Literature DB >> 32226274

The Use of Antiallergic and Antiasthmatic Drugs in Viral Infections of the Upper Respiratory Tract.

Nils Åberg1.   

Abstract

Despite their frequency, upper respiratory tract infections (URTIs) constitute an area with few, if any, effective treatment remedies. Asthma and airway allergies share similar pathogenetic mechanisms to URTIs and it is not surprising, therefore, that agents used to treat allergic disorders have also been studied in URTIs. Their possible effects, limitations and hypothetical modes of action in URTIs are reviewed. In controlled clinical trials of satisfactory scientific standard, symptom reductions in both experimental rhinovirus infections and natural colds have occurred with topical anticholinergics, oral antihistamines and topical chromones. Future treatment alternatives for URTIs may include the intranasal anticholinergic ipratropium bromide, new nonsedating antihistamines and sodium cromoglycate (cromolyn sodium). The latter has a record of safety and an absence of adverse effects that would make it an attractive alternative for this common but not particularly serious condition in otherwise healthy individuals. © Adis International Limited 1996.

Entities:  

Keywords:  Allergy Clin Immunol; Ipratropium Bromide; Nedocromil; Nedocromil Sodium; Sodium Cromoglycate

Year:  2012        PMID: 32226274      PMCID: PMC7100695          DOI: 10.1007/BF03259516

Source DB:  PubMed          Journal:  Clin Immunother        ISSN: 1172-7039


  87 in total

1.  Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects.

Authors:  N J Gross; E Co; M S Skorodin
Journal:  Chest       Date:  1989-11       Impact factor: 9.410

2.  Enhancement by parainfluenza 3 infection of contractile responses to substance P and capsaicin in airway smooth muscle from the guinea pig.

Authors:  R Saban; E C Dick; R I Fishleder; C K Buckner
Journal:  Am Rev Respir Dis       Date:  1987-09

3.  Viruses as precipitants of asthmatic attacks in children.

Authors:  T E Minor; E C Dick; A N DeMeo; J J Ouellette; M Cohen; C E Reed
Journal:  JAMA       Date:  1974-01-21       Impact factor: 56.272

4.  Inhibitory actions of procaterol, a beta-2 stimulant, on substance P-induced cough in normal subjects during upper respiratory tract infection.

Authors:  U Katsumata; K Sekizawa; H Inoue; H Sasaki; T Takishima
Journal:  Tohoku J Exp Med       Date:  1989-05       Impact factor: 1.848

5.  A randomized controlled trial of glucocorticoid prophylaxis against experimental rhinovirus infection.

Authors:  B M Farr; J M Gwaltney; J O Hendley; F G Hayden; R M Naclerio; T McBride; W J Doyle; J V Sorrentino; D K Riker; D Proud
Journal:  J Infect Dis       Date:  1990-11       Impact factor: 5.226

6.  Respiratory tract infections increase susceptibility to neurogenic inflammation in the rat trachea.

Authors:  D M McDonald
Journal:  Am Rev Respir Dis       Date:  1988-06

7.  Parainfluenza virus type 1 reduces the affinity of agonists for muscarinic receptors in guinea-pig lung and heart.

Authors:  A D Fryer; E E el-Fakahany; D B Jacoby
Journal:  Eur J Pharmacol       Date:  1990-05-31       Impact factor: 4.432

Review 8.  Glucocorticoids and infection.

Authors:  J N Aucott
Journal:  Endocrinol Metab Clin North Am       Date:  1994-09       Impact factor: 4.741

9.  Intranasally and orally administered antihistamine treatment of experimental rhinovirus colds.

Authors:  M J Gaffey; J M Gwaltney; A Sastre; W E Dressler; J V Sorrentino; F G Hayden
Journal:  Am Rev Respir Dis       Date:  1987-09

10.  The effect of inhaled and intranasal sodium cromoglycate on symptoms of upper respiratory tract infections.

Authors:  N Aberg; B Aberg; K Alestig
Journal:  Clin Exp Allergy       Date:  1996-09       Impact factor: 5.018

View more
  1 in total

1.  Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.

Authors:  Zahra Molavi; Sara Razi; Seyed Amir Mirmotalebisohi; Amirjafar Adibi; Marzieh Sameni; Farshid Karami; Vahid Niazi; Zahra Niknam; Morteza Aliashrafi; Mohammad Taheri; Soudeh Ghafouri-Fard; Shabnam Jeibouei; Soodeh Mahdian; Hakimeh Zali; Mohammad Mehdi Ranjbar; Mohsen Yazdani
Journal:  Biomed Pharmacother       Date:  2021-03-31       Impact factor: 6.529

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.